Company Overview - The closing price of Aojing Medical (688613.SH) on February 12, 2026, was 23.98 yuan, with a daily decline of 3.54% and a trading volume of 1.10 billion yuan, indicating a turnover rate of 3.31% [1] - As of February 12, the company's price-to-earnings ratio (TTM) was -910.15 times, and the price-to-book ratio was 2.29 times. The revenue forecast for 2025 is 224 million yuan, with a net profit attributable to the parent company of 13.53 million yuan, although the non-recurring net profit is expected to be a loss of 510,000 yuan [3] Industry Analysis - The medical device sector has seen a cumulative decline of 5.39% over the past 20 days, reflecting overall weak performance. Concerns regarding the continuity of medical procurement policies and increased risk aversion ahead of the long holiday have put pressure on small and medium-sized pharmaceutical stocks [4] Market Activity - On February 10, the stock price surged by 5.13% to 25.41 yuan, reaching a new high for the period. The subsequent decline on February 12 is viewed as a technical correction following a significant short-term increase [5] - The financing activity showed a recent trend of increased activity followed by a decline, with a net buy of 9.29 million yuan on February 10, but a net outflow of 7.63 million yuan on February 11, leading to a financing balance of 227 million yuan on February 12. The net outflow of main funds on February 12 indicates a profit-taking pressure from retail investors, who accounted for 38% of the inflow [2]

Core Viewpoint - The company, Kehua Bio, forecasts a significant net loss for the year 2025, estimating a loss of between 5.80 billion to 7.40 billion yuan for net profit attributable to shareholders, and a loss of 5.90 billion to 7.50 billion yuan for net profit after deducting non-recurring gains and losses. This reflects the challenges faced in the IVD industry due to intensified competition and adverse policy impacts [1]. Summary by Relevant Sections Financial Performance - The company anticipates a net loss of 5.80 billion to 7.40 billion yuan for 2025, with a net loss of 5.90 billion to 7.50 billion yuan after excluding non-recurring items [1]. Factors Affecting Performance - Major factors impacting performance include: 1. Asset impairment provisions significantly affecting profits, as the company conducts comprehensive assessments and plans to recognize impairment losses based on industry trends and operational realities [1]. 2. Increased market competition and adverse industry policies leading to a decline in both volume and price, resulting in reduced revenue and gross margin [1]. 3. The company is committed to its strategic positioning of "comprehensive yet precise" and "integrated innovation," focusing on national health needs while implementing various measures for stable development [1]. Strategic Initiatives - The company plans to: 1. Strengthen research and sales collaboration to uncover new growth drivers, maintaining R&D investment and enhancing its sales and service network domestically and internationally [1]. 2. Deepen lean management and promote digital transformation to optimize resource allocation and improve operational efficiency, thereby laying a solid foundation for high-quality development [1].

Core Viewpoint - Gongdong Medical (605369) is expected to report a significant decline in net profit for 2025, with projections ranging from 44 million to 56 million yuan, representing a year-on-year decrease of 67.37% to 74.36% [2] Group 1: Financial Performance - The company anticipates a net profit attributable to the parent company of 44 million to 56 million yuan for 2025 [2] - This forecast indicates a substantial decline in profitability compared to the previous year, with a decrease of 67.37% to 74.36% [2] Group 2: Operational Challenges - The decline in performance is attributed to the operating results of its subsidiary, Trademark Plastics Inc. (TPI), which have been negatively impacted by international trade policies and fluctuations in shipping costs [2] - Additionally, the company faces challenges from U.S. tariff policies and domestic medical "group purchasing" policies, leading to a slowdown in demand for some of its products [2]

Core Viewpoint - The company, Gongdong Medical (605369.SH), anticipates a significant decline in net profit for the fiscal year 2025, with projections indicating a decrease of 67.37% to 74.36% compared to the previous year [1] Financial Projections - The expected net profit attributable to the parent company's owners for 2025 is estimated to be between 44 million to 56 million yuan [1] - The projected net profit, excluding non-recurring gains and losses, is forecasted to be between 54 million to 66 million yuan, reflecting a year-on-year decrease of 60.75% to 67.89% [1] Business Impact - The company's business has been adversely affected by the U.S. tariff policies and domestic medical "collection" policies, leading to a slowdown in demand for certain products [1] - As a result of the aforementioned factors, the gross profit margin for related business segments has experienced a decline [1]

Core Viewpoint - Gongdong Medical (605369) expects a significant decline in net profit for 2025, projecting a range of 44 million to 56 million yuan, which represents a year-on-year decrease of 67.37% to 74.36% [1] Group 1: Financial Performance - The company anticipates a net profit attributable to the parent company of 44 million to 56 million yuan for 2025 [1] - This projected profit decline is attributed to various factors, including international trade policies and fluctuations in shipping costs affecting the performance of its subsidiary, Trademark Plastics Inc. (TPI) [1] Group 2: Market Conditions - The company is facing challenges due to the impact of U.S. tariff policies and domestic medical "group purchasing" policies, which have led to a slowdown in demand growth for some of its products [1]

Core Viewpoint - Gongdong Medical (605369) reported a slight increase in revenue but a significant decline in net profit for the first half of 2025, primarily due to external economic factors and internal operational challenges [1] Financial Performance - The company achieved an operating revenue of 557 million yuan, representing a year-on-year growth of 0.58% [1] - The net profit attributable to shareholders was 50.35 million yuan, reflecting a year-on-year decrease of 47.16% [1] - Basic earnings per share stood at 0.23 yuan [1] Contributing Factors - The decline in net profit was attributed to several factors, including: - The impact of U.S. tariff policies and domestic medical procurement policies leading to a decrease in product prices [1] - Losses from investment income due to the disposal of equity accounted for using the equity method from the acquisition of Jindongsheng [1] - Reduced exchange gains due to fluctuations in the U.S. dollar exchange rate [1] - Decreased interest income during the reporting period [1]